本文由小咖机器人翻译整理

期刊来源：Nat Med

原文链接：https://doi.org/10.1038/s41591-024-02996-7

摘要内容如下：

在选择心血管结果试验中，Semaglutide显示，在17，604名已患心血管疾病、超重或肥胖且无糖尿病的成年人中，主要不良心血管事件减少了20%。在这个预先指定的分析中，我们通过基线身体质量指数（BMI）检查了semaglutide对体重和人体测量结果、安全性和耐受性的影响。在接受semaglutide治疗的患者中，体重下降持续超过65周，并持续长达4年。在208周时，与安慰剂相比，semaglutide与体重（-10.2%）、腰围（-7.7cm）和腰围身高比（-6.9%）的平均减少相关（分别为-1.5%、-1.3cm和-1.0%；与安慰剂相比，所有比较P<0.0001）。有临床意义的体重减轻发生在两性和所有种族、体型和地区。Semaglutide与较少的严重不良事件相关。对于每个BMI类别（<30、30至<35、35至<40和≥40kgm-2），Semaglutide的严重不良事件发生率（每观察100年的事件）较低（Semaglutide为43.23、43.54、51.07和47.06，安慰剂为50.48、49.66、52.73和60.85）。Semaglutide与试验产品停药率增加相关。随着体重指数（BMI）等级的降低，停药率增加。在208周的SELECT中，与安慰剂相比，Semaglutide产生了临床上显著的体重减轻和人体测量指标的改善。体重减轻持续4年以上。ClinicalTrials.gov标识符：NCT03574597。

英文原文如下：

Abstracts

In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI). In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%), waist circumference (-7.7 cm) and waist-to-height ratio (-6.9%) versus placebo (-1.5%, -1.3 cm and -1.0%, respectively; P < 0.0001 for all comparisons versus placebo). Clinically meaningful weight loss occurred in both sexes and all races, body sizes and regions. Semaglutide was associated with fewer serious adverse events. For each BMI category (<30, 30 to <35, 35 to <40 and ≥40 kg m-2) there were lower rates (events per 100 years of observation) of serious adverse events with semaglutide (43.23, 43.54, 51.07 and 47.06 for semaglutide and 50.48, 49.66, 52.73 and 60.85 for placebo). Semaglutide was associated with increased rates of trial product discontinuation. Discontinuations increased as BMI class decreased. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss and improvements in anthropometric measurements versus placebo. Weight loss was sustained over 4 years. ClinicalTrials.gov identifier: NCT03574597 .

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。